One hundred forty-three non-diabetic adult RA patients ( 76.2 % female , age 55.2 12.1 [ mean SD ] ) on stable RA standard of care treatment were enrolled in a randomized , double-blind placebo controlled crossover trial of 45 mg daily pioglitazone versus placebo , with a 3-month duration/arm and a 2-month washout period .